Tau Receptor Antagonists to Block Neuronal Tau Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The progression of Alzheimer's disease is linked to the trans-synaptic transfer and uptake of tau protein, mediated by unidentified receptors, leading to neurofibrillary tangle accumulation and cognitive decline, with existing treatments lacking effective targets for intervention.
Innovation Solution
LRP1 and SorLA are identified as endocytic receptors for tau, and their antagonists, such as RAP and specific antibodies, are used to inhibit tau internalization and trafficking, thereby preventing the spread of tau aggregates and reducing cognitive decline.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LRP1 and SorLA receptors mediate tau internalization and trafficking, then tau aggregates spread between neurons leading to neurofibrillary tangle accumulation, but blocking these receptors with antagonists is needed to prevent disease progression
Solution Approach 1:
The patent uses RAP (Receptor-Associated Protein) and specific antibodies as intermediary molecules that bind to LRP1 and/or SorLA receptors, blocking tau protein interaction with these receptors. This intermediary approach prevents tau internalization without directly modifying the receptors or tau protein structure, thereby stopping the harmful spread of tau aggregates between neurons while maintaining normal receptor function for other ligands
Solution Approach 2:
The invention extracts and isolates the specific binding interaction between tau and the LRP1/SorLA receptor complex by using highly specific antagonists. This extraction of the pathological interaction allows selective inhibition of tau uptake while preserving other physiological functions of these receptors, addressing the contradiction between blocking harmful tau internalization and maintaining normal cellular processes
2Ease of manufacture
If existing treatments lack effective targets for intervention, then Alzheimer's disease progression cannot be effectively halted, but identifying LRP1 and SorLA as tau receptors provides new therapeutic targets
Solution Approach 1:
The patent performs preliminary identification and characterization of LRP1 and SorLA as tau receptors before developing therapeutic interventions. By establishing the receptor-tau interaction mechanism in advance, the invention creates a foundation for subsequent drug development, making therapeutic intervention more accessible and reliable
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific general approaches to specific receptor-targeted interventions. By identifying LRP1 and SorLA as specific targets and developing antagonists with defined binding characteristics, the patent transforms the treatment approach to enable reliable and effective intervention in tau-mediated neurodegeneration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibiting the interaction between tau and LRP1 or SorLA through antagonists like RAP reduces tau internalization, potentially slowing the progression of Alzheimer's disease and preventing neurofibrillary tangle formation.
Implementation Method 1
LRP1 functions as an endocytic receptor for tau that mediates its internalization into cells
Data Source
AI summary
The present invention provides methods and compositions for reducing internalization and/or trafficking of tau in neuronal cells comprising contacting the cells with an effective amount of an LRP1 and/or SorLA antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of an LRP1 and/or SorLA antagonist.